Skip to cookie consent Skip to main content

Mass General Brigham Heart Experts to Present Data and Insights on Treatment and Prevention at ESC Congress 2025

3 minute read
  • Sessions will highlight advancements and opportunities in heart failure prevention as well as potential treatments for heart failure, including GLP-1RAs
  • Late-breaking trial results and simultaneous publications on treatments targeting inflammation, triglycerides, and more

Researchers from Mass General Brigham will present discoveries and outcomes from clinical trials and research studies for cardiovascular conditions, including heart disease and heart failure, at the European Society of Cardiology (ESC) Congress, being held in Madrid, Spain, from Aug. 29–Sept. 1.

Below are a few highlights from this year’s presentations.

Paul Ridker, MD headshot

hsCRP and Long-term CV Outcomes among SMuRF-Less Women

When: August 29, 2025, at 08:45 CEST // 02:45 EDT

Speaker: Paul M. Ridker, MD, MPH

What: This late breaking clinical science is embargoed until the scheduled start time of the presentation and the paper’s publication in The European Heart Journal.

The Lancet Series: Prioritising Heart Failure Prevention and Addressing Disparities in Cardiovascular Health

When: August 29, 2025, at 13:45 CEST // 07:45 EDT

Speakers:

What: This session will accompany a series of simultaneous publications in The Lancet, exploring risk factors contributing to heart failure, current and emerging prevention strategies, and factors that contribute to inequalities and disparities in cardiovascular outcomes. Details are embargoed until the time of simultaneous publication.

David D. Berg, MD, MPH

DAPA ACT HF-TIMI 68: Dapagliflozin in Patients Hospitalized for Acute Heart Failure

When: August 30, 2025, at 08:15 CEST // 02:15 EDT

Speaker: David Berg, MD, MPH

What: This hot line session is embargoed until the scheduled start time of the presentation and the paper’s simultaneous publication in Circulation.

Brian Bergmark, MD

Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: the Essence-TIMI 73b trial

When: August 30, 2025, at 16:45 CEST // 10:45 EDT

Speaker: Brian Bergmark, MD

What: This hot line session is embargoed until the scheduled start time of the presentation and the paper’s simultaneous publication.

Gregory Piazza, MD, MS

HI-PRO: Apixaban for Extended Treatment of Provoked Venous Thromboembolism

When: August 30, 2025, at 18:15 CEST // 12:15 EDT

Speaker: Gregory Piazza, MD

What: This hot line session is embargoed until the scheduled start time of the presentation and the paper’s simultaneous publication.

Semaglutide and Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction

When: August 31, 2025, at 09:30 CEST // 03:30 EDT

Speaker: Nils Kruger, PhD

What: This late breaking clinical science is embargoed until the scheduled start time of the presentation and the paper’s publication in JAMA.

Thomas Andrew Gaziano, MD, MSC

IMPACT-BP Implementation of a Combination Intervention for Sustainable Blood Pressure Control in rural South Africa

When: September 1, 2025, at 09:21 CEST // 03:21 EDT

Speaker: Thomas Andrew Gaziano, MD

What: This hot line session is embargoed until the scheduled start time of the presentation and the paper’s publication.

Jason H. Wasfy, MD, MPhil

Aortic valve replacement in asymptomatic individuals with severe aortic stenosis and left ventricular hypertrophy

When: September 1, 2025, at 10:15 CEST // 04:15 EDT

Presenter: Jason Wasfy, MD

What: Data will be presented as part of the multi-valve disease e-poster session and simultaneously published. Results are embargoed until the time of publication in the European Journal of Cardio-Thoracic Surgery.

Media contact

Brandon Chase
Senior Specialist, External Communications
bchase7@mgb.org

About Mass General Brigham

Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.